We investigate the usefulness of administering G47Δ (teserpaturev), a triple-mutated oncolytic herpes simplex virus type 1, prior to resection...G47Δ therapy caused increased number of tumor-infiltrating CD8 and CD4 cells, increased F4/80 cells within the residual tongues, and increased expression of immune-related genes in and around the tumor. These results imply that neoadjuvant use of G47Δ is useful for preventing local recurrence after tongue cancer surgery.
1 year ago
Preclinical • Journal • Oncolytic virus
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
"Delytact" is a viral-gene therapy that targets malignant brain tumors, such as malignant gliomas, while "Stemirac" targets against spinal contusion via self-mesenchymal implantation. Both are permitted clinical arsenals in Japan.